Differential gradients of efficacy of immunotherapy according to the sun-exposure pattern of the site of occurrence of primary melanoma: A multicenter prospective cohort study (MELBASE).
David Russo(Hôpital Pontchaillou), Lise Boussemart(Centre National de la Recherche Scientifique), Bastien Oriano(Hôtel-Dieu de Paris), M.‐T. Leccia(Centre Hospitalier Universitaire de Grenoble), Florence Granel Brocard(Centre Hospitalier Régional et Universitaire de Nancy), O. Dereure(Beth Israel Deaconess Medical Center), Wendy Lefevre(Inserm), Célèste Lebbé(Inserm), S. Dalac(CHU Dijon Bourgogne), Jean‐Philippe Arnault(Centre Hospitalier Universitaire Amiens-Picardie), Julie De Quatrebarbes(Centre Hospitalier Annecy Genevois), Henri Montaudié(Hôpital l'Archet), E. Maubec(Délégation Paris 7), Délphine Legoupil(Centre Hospitalier Régional Universitaire de Brest), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Clara Allayous(Inserm), Stéphane Dalle(Mount Sinai Hospital), Laurent Mortier, Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), Brigitte Dréno(Inserm)
Cited by 4
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k